Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results

被引：3
|
作者：
Hess, Georg [1 ]
Karola, Wagner [2 ]
LaRosee, Paul [3 ]
Keller, Ulrich [4 ]
Atta, Johannes [5 ]
Witzens-Harig, Mathias [6 ]
Crombe, Anne [7 ]
Medler, Christoph [8 ]
Borchmann, Peter [9 ,10 ]
Bitz, Ulrich [11 ]
Lerchenmuller, Christian [12 ]
Theobald, Matthias [1 ]
Dreyling, Martin H. [13 ]
机构：
[1] Johannes Gutenberg Univ Med Ctr, III Dept Med, Mainz, Germany
[2] Charite, Gerlingen, Germany
[3] Jena Univ Hosp, Jena, Germany
[4] Tech Univ Munich, Munich, Germany
[5] Goethe Univ Frankfurt, Frankfurt, Germany
[6] Univ Heidelberg Hosp, Dept Internal Med V, Heidelberg, Germany
[7] Univ Mainz Hosp, Interdisciplinary Ctr Clin Trials IZKS, Mainz, Germany
[8] IZKS, Mainz, Germany
[9] Univ Hosp Cologne, Dept I Internal Med, Cologne, Germany
[10] Univ Hosp Cologne, German Hodgkin Study Grp GHSG, Cologne, Germany
[11] HELIOS Klin Bad Saarow, Bad Saarow Pieskow, Germany
[12] Outpatient Clin, Hematol & Oncol, Munster, Germany
[13] Univ Hosp Grosshadern LMU, Dept Med III, Munich, Germany
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2977.2977
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2977
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma
    Ito, Kaori
    Okamoto, Masataka
    Ando, Maiko
    Kakumae, Yukiko
    Okamoto, Akinao
    Inaguma, Yoko
    Tokuda, Masutaka
    Yanada, Masamitsu
    Yamada, Shigeki
    Emi, Nobuhiko
    LEUKEMIA & LYMPHOMA, 2015, 56 (04) : 1123 - 1125
  • [22] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Garbo, Lawrence E.
    Flynn, Patrick J.
    MacRae, Margaret A.
    Rauch, Mary A.
    Wang, Yunfei
    Kolibaba, Kathryn S.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (05) : 476 - 481
  • [23] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Lawrence E. Garbo
    Patrick J. Flynn
    Margaret A. MacRae
    Mary A. Rauch
    Yunfei Wang
    Kathryn S. Kolibaba
    Investigational New Drugs, 2009, 27 : 476 - 481
  • [24] Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings
    Czuczman, Myron S.
    Goy, A.
    Lamonica, D.
    Graf, D. A.
    Munteanu, M. C.
    van der Jagt, R. H.
    ANNALS OF HEMATOLOGY, 2015, 94 (12) : 2025 - 2032
  • [25] Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings
    Myron S. Czuczman
    A. Goy
    D. Lamonica
    D. A. Graf
    M. C. Munteanu
    R. H. van der Jagt
    Annals of Hematology, 2015, 94 : 2025 - 2032
  • [26] Bendamustine and rituximab for the treatment of relapsed indolent and mantle cell lymphoma: when timing of a study matters
    Falchi, Lorenzo
    Morales, Rita
    Ruella, Marco
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S590 - S594
  • [27] Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial
    Wang, Michael
    Hagemeister, Fredrick
    Westin, Jason R.
    Fayad, Luis
    Samaniego, Felipe
    Turturro, Francesco
    Chen, Wendy
    Zhang, Liang
    Badillo, Maria
    DeLa Rosa, Maria
    Addison, Alicia
    Kwak, Larry W.
    Romaguera, Jorge E.
    BLOOD, 2014, 124 (21)
  • [28] A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma
    Kim, Myung Sun
    Banerjee, Titas
    Chen, Andy
    Danilov, Alexey
    MacKinnon, Renee
    Thurlow, Bria
    Thakurta, Sujata
    Orand, Kirsten
    Degnin, Catherine
    Park, Byung
    Spurgeon, Stephen E.
    LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 722 - 724
  • [29] Preliminary results of a phase I/II study of weekly or twice weekly bortezomib in combination with rituximab, in patients with follicular lymphoma, mantle cell lymphoma and Waldenstrom's macroglobulinaemia
    Agathocleous, A.
    Rule, S.
    Johnson, P.
    Radford, J. A.
    Lafon, N.
    Hunter, H.
    Kerr, J. P.
    Neeson, S. M.
    Matthews, J.
    Strauss, S.
    Montoto, S.
    Rohatiner, A. Z. S.
    Lister, T. A.
    BLOOD, 2007, 110 (11) : 754A - 754A
  • [30] Phase I/II study of a new salvage chemotherapy with rituximab (CHASER therapy) for relapsed advanced follicular lymphoma (FL) and mantle cell lymphoma (MCL).
    Ogura, M
    Kikuchi, A
    Kawase, T
    Kajimoto, K
    Kamiya, Y
    Taji, H
    Kagami, Y
    Morishima, Y
    BLOOD, 2002, 100 (11) : 294B - 294B
12345